A Study of the Safety and Pharmacokinetics of CNTO 136 in Patients With Cutaneous Lupus Erythematosus and Systemic Lupus Erythematosus

NCT01702740 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

49

Enrollment

INDUSTRY

Sponsor class

Conditions

Lupus Erythematosus, Cutaneous
Lupus Erythematosus, Systemic

Interventions

DRUG: 1 mg/kg CNTO 136
DRUG: 4 mg/kg CNTO 136
DRUG: 10 mg/kg CNTO 136
DRUG: Placebo

Sponsor

Centocor Research & Development, Inc.